Basilea Pharmaceutica (BSLN) Investor Presentation summary

Company overview

• Founded in 2000 as a Roche spin-off, Basilea is a profitable Swiss biopharma focused on anti-infectives, with about 160 employees and listed on SIX Swiss Exchange.

• Executive team brings deep expertise across R&D, clinical, and commercial functions.

• Headquarters in Allschwil, Switzerland, within the Basel life sciences hub.

Strategic focus and business model

• Focuses on severe bacterial and fungal diseases with high unmet medical needs, such as resistance and lack of oral therapies.

• Business model prioritizes identifying high-value anti-infective opportunities, in-licensing, and risk-adjusted portfolio management.

• Maintains a lean structure by leveraging external partners for commercialization and manufacturing.

• Accesses non-dilutive funding and stops projects lacking compelling risk-return profiles.

Partnerships and global reach

• Commercializes products through global, regional, and local partners, including Pfizer, Astellas, Asahi Kasei, and others.

• Over 100 countries covered for Cresemba through partnerships.

• Offsets R&D expenses via non-dilutive funding from organizations like BARDA and CARB-X.